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Trends in Caffeine Use and Association between Clinical Outcomes
and Timing of Therapy in Very Low Birth Weight Infants
Nicole R. Dobson, MD1,*, Ravi M. Patel, MD2,*, P. Brian Smith, MD, MPH, MHS3, Devon R. Kuehn, MD4, Jennifer Clark, PhD5,
Shilpa Vyas-Read, MD2, Amy Herring, ScD5, Matthew M. Laughon, MD, MPH6, David Carlton, MD2, and Carl E. Hunt, MD1
Objective To examine the effect of early initiation of caffeine therapy on neonatal outcomes and characterize the
use of caffeine therapy in very low birth weight (VLBW) infants.
Study design We analyzed a cohort of 62 056 VLBW infants discharged between 1997 and 2010 who received
caffeine therapy.We compared outcomes in infants receiving early caffeine therapy (initial dose before 3 days of life)
and those receiving late caffeine therapy (initial dose at or after 3 days of life) through propensity scoring using base-
line and early clinical variables. The primary outcome was the association between the timing of caffeine initiation
and the incidence of bronchopulmonary dysplasia (BPD) or death.
Results We propensity score–matched 29 070 VLBW infants at a 1:1. Of infants receiving early caffeine therapy,
3681 (27.6%) died or developed BPD, comparedwith 4591 infants (34.0%) receiving late caffeine therapy (OR, 0.74;
99% CI, 0.69-0.80). Infants receiving early caffeine had a lower incidence of BPD (23.1% vs 30.7%; OR, 0.68; 95%
CI, 0.63-0.73) and a higher incidence of death (4.5% vs 3.7%; OR, 1.23; 95% CI, 1.05-1.43). Infants receiving early
caffeine therapy had less treatment of patent ductus arteriosus (OR, 0.60; 95%CI, 0.55-0.65) and a shorter duration
of mechanical ventilation (mean difference, 6 days; P < .001).
Conclusion Early caffeine initiation is associated with a decreased incidence of BPD. Randomized trials are
needed to determine the efficacy and safety of early caffeine prophylaxis in VLBW infants. (J Pediatr
2014;164:992-8).
See editorial, p 957
C
affeine is one of the most commonly prescribed medications in preterm infants.1 In the Caffeine for Apnea of Prema-
turity (CAP) trial published in 2006, infants allocated to receive caffeine had a lower incidence of bronchopulmonary
dysplasia (BPD) compared with control infants.2 In early follow-up at age 18-21 months, improved neurodevelopmen-
tal outcomes, including a lower incidence of cerebral palsy, were noted in infants allocated to receive caffeine, but these benefits
were not as dramatic at age 5 years.3,4
Approximately one-half of the early neurodevelopmental improvement of caffeine therapy was explained by improved res-
piratory morbidity, including an approximate 1-week reduction in the duration of mechanical ventilation (MV).2 Caffeine may
decrease pulmonary morbidity through its beneficial effects on respiratory mechanics,5-8 and possibly by protecting lung tissue
against damage from injury.9-11 Given the demonstrable benefits of caffeine, un-
derstanding its current clinical use is of significant value.
Several aspects of caffeine therapy remain unknown. For example, a post hoc
analysis of the CAP trial suggests that early caffeine therapy (ie, initiation before
day of life [DOL] 3) is associated with decreased use of endotracheal intubation
and positive pressure ventilation when compared with late caffeine therapy (ie,
initiation at or after DOL 3).12 The risks and benefits of early caffeine therapy
compared with late caffeine therapy and the routine use of caffeine prophylaxis
have not been yet evaluated in a randomized, controlled trial. In our recent inves-
tigation of the association of timing of caffeine therapy and clinical outcomes in a
single-center, retrospective study, infants with early initiation of caffeine therapy
demonstrated decreased risk of BPD and patent ductus arteriosus (PDA).13 In
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BPD Bronchopulmonary dysplasia
CAP Caffeine for Apnea of Prematurity
CPAP Continuous positive airway pressure
DOL Day of life
GA Gestational age
FiO2 Fraction of inspired oxygen
HFOV High-frequency oscillatory ventilation
IVH Intraventricular hemorrhage
MV Mechanical ventilation
NEC Necrotizing enterocolitis
PDA Patent ductus arteriosus
PS Propensity score
ROP Retinopathy of prematurity
VLBW Very low birth weight
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addition, trends in the use of caffeine citrate, approved by the
Food and Drug Administration in 1999,14 have yet to be
studied in a large population of very low birth weight
(VLBW) infants. Caffeine has several advantages over other
methylxanthines, including a long half-life and a wide thera-
peutic window that does not require therapeutic drug moni-
toring.15
We compared the effects of early and late caffeine therapy
on short-term neonatal outcomes, including death and BPD,
among others, in a large group of US neonatal intensive care
units. We also characterized the use of methylxanthines from
1997 to 2010. We hypothesize that: (1) early caffeine initia-
tion is associated with improved neonatal outcomes; (2)
centers have shifted to earlier initiation of caffeine therapy;
and (3) caffeine has replaced the use of aminophylline and
theophylline in the current era.
Methods
We used a large, multicenter dataset from the Pediatrix Med-
ical Group.16 The use of this dataset has been described pre-
viously.1 Infants discharged between 1997 and 2010 were
eligible for evaluation of primary and secondary outcomes
if they met the following inclusion criteria: (1) receipt of
caffeine during the course of hospitalization; (2) VLBW
(<1500 g birth weight); and (3) admission within 1 day of
birth. Exclusion criteria included treatment with multiple
methylxanthines and early mortality (death on DOL 0-3).
In addition, we examined all VLBW infants discharged
between 1997 and 2010, including infants not treated with
caffeine or treated with other methylxanthines (theophylline
and aminophylline), to characterize trends in the use of
methylxanthines. This study was approved by the Duke Uni-
versity Medical Center Institutional Review Board.
Postnatal age was based on DOL, with the day of birth
defined as DOL 0. We compared patient characteristics and
outcomes by timing of initiation of caffeine therapy, with
early defined as initiation before DOL 3 and late defined at
initiation on or after DOL 3. We determined the type of
respiratory support provided for all infants and the duration
of respiratory support for infants requiringMV. Our primary
outcome measure was the association between timing of
initiation of caffeine therapy and incidence of BPD or death.
We calculated mortality for all infants who died before
hospital discharge. We defined BPD as the need for any
respiratory support at postmenstrual age 36 0/7-36 6/7 weeks
if <32 weeks gestational age (GA) at birth or at 28-34 post-
natal days if$32 weeks GA at birth. Infants discharged before
the BPD evaluation period on room air were defined as
having no BPD, and those receiving respiratory support
before the evaluation period were defined as missing for
BPD status.
To account for the competing outcomes of mortality and
BPD, we used a composite outcome measure of BPD or
death. Secondary outcomes were prespecified and selected
based on clinical outcomes that potentially could be affected
by caffeine therapy based on results from our previous
study13 and the CAP trial.2 We defined treatment of a PDA
as the receipt of either indomethacin or ibuprofen therapy
for closure of a PDA after DOL 3 or surgical ligation. We
defined late-onset sepsis as a positive blood culture on or
after DOL 3. We defined necrotizing enterocolitis (NEC) as
the diagnosis of medical or surgical NEC. Additional
neonatal comorbidities were identified by the diagnosis of
the corresponding morbidity in the patient’s medical record.
To reduce bias and confounding related to treatment with
early caffeine, we used propensity score (PS) matching to
obtain similar matched populations of infants receiving early
and late caffeine therapy. Matching was chosen over other PS
methods, such as stratifying on the quintiles, for ease of inter-
pretation and because greater residual imbalance tends to be
eliminated bymatching.17 For the PSmodel, we used baseline
demographic and early clinical variables that could predict
early caffeine treatment and/or were predictors of our
primary outcome.18 The following baseline variables were
used in the PS model: GA, birth weight, sex, race, small for
GA status, Apgar score at 5 minutes, receipt of antenatal
steroids, outborn, center, and birth year. In addition, the
following early clinical variables were used: apnea on DOL
0 or 1, level of respiratory support on DOL 1, maximal frac-
tion of inspired oxygen (FiO2) onDOL 1, and the use of high-
frequency oscillatory ventilation (HFOV) on DOL 1.
A greedy match algorithm was used to match infants
receiving early and late caffeine therapy.19 Patients were
matched without replacement down to a 1-digit match,
and any patients who could not be matched beyond this level
were excluded.
For unmatched patients, the Wald c2 test with adjustment
for clustering by center was used for categorical variables, and
the Student t test or Wilcoxon rank-sum test was used for
continuous variables. For PS-matched patients, the McNe-
mar test for categorical variables was used for binary categor-
ical variables, the Bhakpar generalized McNemar test was
used for multiple categorical variables, and the paired t test
or Wilcoxon rank-sum test was used for continuous vari-
ables. Trends in the use of methylxanthines over time were
evaluated using the Spearman rank correlation coefficient.
All statistical analyses were performed using SAS version
9.2 (SAS Institute, Cary, North Carolina). A P value <.01
was considered significant.
Results
Of the 54 707 infants meeting the study’s inclusion criteria,
29 070 (53%) were PS-matched at 1:1 (Figure 1). PS-
matched infants in the early and late caffeine groups had
similar baseline characteristics, with no significant
differences in any of the matched variables, including mean
birth weight (1055 g vs 1054 g; P = .77) and GA (28.1
weeks vs 28.0 weeks; P = .70) (Table I).
Early Respiratory Characteristics
After matching, statistically significant, but minimal
differences were seen between infants receiving early and
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late caffeine therapy in the rates of continuous positive airway
pressure (CPAP) therapy (22.4% vs 21.6%), conventional
ventilation (49.7% vs 51.4%), and HFOV (11.9% vs 10.9%)
on DOL 1 (P = .002). The mean maximal FiO2 on DOL 1
was similar in the 2 groups (0.27 vs 0.27; P = .74) (Table I).
Infants in the early caffeine therapy group were more likely
to receive higher levels of respiratory support, including
MV and HFOV, at the initiation of caffeine therapy
(Table II; available at www.jpeds.com).
Clinical Characteristics
There was no difference in the incidence of NEC (P = .50)
between the PS-matched groups (Table III). The incidence
of central nervous system complications, including any
intraventricular hemorrhage (IVH) (P < .001), severe (grade
3 or 4) IVH (P < .001), and periventricular leukomalacia
(P = .001), was lower in the early caffeine group, as was the
incidence of retinopathy of prematurity (ROP) (P < .001)
and of ROP requiring treatment (P < .001). The early
caffeine group also demonstrated a lower incidence of
pulmonary interstitial emphysema (P < .001), although this
complication was uncommon in both groups.
In the early caffeine group, the mean age at initiation of
therapy was DOL 1 (Table III), with the majority of infants
starting treatment within a day after birth (Figure 2;
available at www.jpeds.com). In comparison, the late
caffeine group had a wide range of age at initiation, with the
mean of DOL 11. Surfactant use was similar in the 2 groups
(P = .17). In addition, the rate of prophylactic indomethacin
use was lower in the early caffeine group (P < .001).
Primary Outcome
For the primary outcome of BPD or death, the early caffeine
group had a lower odds of BPD or death (OR, 0.74; 99% CI,
Figure 1. After PS matching, 29070 patients (53%) meeting
the inclusion criteria were eligible for analysis of primary and
secondary outcomes. *Patients receiving multiple methylxan-
thines included in the evaluation of trends in methylxanthine
use over time. **Select comparisons of the full cohort meeting
inclusion and exclusion criteria, including unmatched patients.
Table I. Baseline and early clinical characteristics
Characteristics
All patients PS-matched patients*
Early caffeine
(n = 30 891)
Late caffeine
(n = 23 816) P value
Early caffeine
(n = 14 535)
Late caffeine
(n = 14 535) P value
Birth weight, g, mean (5th, 95th percentile) 1076 (650, 1450) 1009 (560, 1450) <.0001 1055 (630, 1447) 1054 (590, 1460) .77
GA, wk, mean (5th, 95th percentile) 28.2 (25.0, 32.0) 27.7 (24.0, 32.0) <.0001 28.1 (25.0, 31.0) 28.0 (24.0, 32.0) .70
Sex, male, n (%) 15 538 (50.3) 12 267 (51.5) .01 7386 (50.8) 7395 (50.9) .92
Race, n (%)†
White 15 051 (50.3) 11 648 (50.6) .88 7467 (51.4) 7511 (51.7) .88
Black 7531 (25.2) 5620 (24.4) 3579 (24.6) 3592 (24.7)
Hispanic 5783 (19.3) 4507 (19.6) 2707 (18.6) 2655 (18.3)
Other 1580 (5.3) 1252 (5.4) 782 (5.4) 777 (5.4)
Multiple gestation, n (%) 8423 (27.3) 6605 (27.7) .33 4017 (27.6) 4036 (27.8) .80
Small for GA, n (%) 2852 (9.2) 2265 (9.5) .42 1383 (9.5) 1343 (9.2) .42
Apgar at 1 min, median (IQR) 6 (4-8) 6 (4-7) <.0001 6 (4-7) 6 (4-7) .29
Apgar at 5 min, median (IQR) 8 (7-9) 8 (7-9) <.0001 8 (7-9) 8 (7-9) .93
Any antenatal steroids, n (%) 24 562 (79.5) 18 123 (76.1) <.0001 11 427 (78.6) 11 475 (79.0) .49
Outborn, n (%)z 3473 (11.3) 3236 (13.8) <.0001 1602 (11.0) 1613 (11.1) .84
Respiratory support on DOL 1, n (%)x
Room air 1936 (6.4) 1804 (7.7) <.0001 1242 (8.5) 1255 (8.6) .002
Hood oxygen 135 (0.5) 102 (0.4) 56 (0.4) 78 (0.5)
Nasal cannula 1048 (3.5) 643 (2.8) 482 (3.3) 440 (3.0)
High-flow nasal cannula 1707 (5.7) 750 (3.2) 544 (3.7) 572 (3.9)
CPAP 9177 (30.4) 3675 (15.8) 3249 (22.4) 3145 (21.6)
MV 13 966 (46.2) 10 830 (46.7) 7230 (49.7) 7465 (51.4)
HFOV 2238 (7.4) 5401 (23.3) 1732 (11.9) 1580 (10.9)
Maximal FiO2 on DOL 1, mean (5th, 95th percentile) 0.26 (0.21, 0.41) 0.30 (0.21, 0.60) <.0001 0.27 (0.21, 0.50) 0.27 (0.21, 0.45) .74
Apnea on DOL 0 or 1, n (%) 8045 (26) 1095 (4.6) <.0001 859 (5.9) 817 (5.6) .16
*Patients PS-matched on all baseline characteristics and early respiratory support variables (except Apgar at 1 min), as well as birth year and center.
†A total of 1735 (3.2%) patients with missing data.
zA total of 514 (0.9%) patients with missing data.
xA total of 1295 (2.4%) patients with missing data.
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0.69-0.80) and a lower odds of BPD in survivors (OR, 0.68;
95% CI, 0.63-0.73) (Table IV). The difference in risk of
BPD between the early and late caffeine groups was 16.1%
before PS matching and 7.6% in matched infants. The early
caffeine group received less respiratory support at 36 weeks
postmenstrual age (Table II). The odds of death were higher
in the early caffeine group (OR, 1.23; 95% CI, 1.05-1.43),
with a risk difference of 0.8%between the 2 groups (Table IV).
To determine whether the outcomes were specific to in-
fants of a particular GA, we performed a subgroup analysis
by GA strata. In this subgroup analysis, early caffeine therapy
was associated with a consistent effect on the odds of BPD in
infants of all GA subgroups (Table V; available at www.jpeds.
com). Infants at <24 weeks GA who received early caffeine
therapy had an increased odds of death, which was not
seen in any of the other GA strata.
Secondary Outcomes
PDA requiring treatment was less frequent in the early caffeine
group (OR, 0.60; 95% CI, 0.55-0.65) (Table IV). Mean weight
Table III. Clinical characteristics
Characteristics
All patients PS-matched patients
Early caffeine
(n = 30 891)
Late caffeine
(n = 23 816) P value
Early caffeine
(n = 14 535)
Late caffeine
(n = 14 535) P value
Comorbidities, n (%)
Early-onset sepsis* 378 (1.3) 455 (2.1) <.001 183 (1.4) 256 (2.0) <.001
Pulmonary interstitial emphysema 428 (1.4) 1148 (4.8) <.001 233 (1.6) 468 (3.2) <.001
IVH 8320 (26.9) 8629 (36.2) <.001 4267 (29.4) 4745 (32.7) <.001
Severe IVH† 1406 (4.6) 2401 (10.1) <.001 755 (5.2) 1103 (7.6) <.001
Periventricular leukomalacia 422 (1.4) 579 (2.4) <.001 228 (1.6) 301 (2.1) .001
NECz 2488 (8.1) 1980 (8.3) .49 1219 (8.4) 1187 (8.2) .50
ROP 9273 (30.0) 9881 (41.5) <.001 4515 (31.1) 5266 (36.2) <.001
Therapy for ROP 745 (2.4) 1650 (6.9) <.001 404 (2.8) 727 (5.0) <.001
Therapies
Age at caffeine initiation, d
Mean (5th,95th percentile) 1 (0,2) 13 (3,45) -x 1 (0,2) 11 (3,37) -x
Median (IQR) 1 (0-1) 7 (4-16) 1 (1-2) 6 (4-12)
Duration of caffeine therapy, d
Mean (5th,95th percentile) 37 (5,72) 33 (5,68) <.001 37 (4,72) 32 (5,67) <.001
Median (IQR) 36 (23-49) 30 (17-45) 36 (22-50) 29 (17-43)
Surfactant use, n (%) 19 856 (64.3) 16 342 (68.6) .002 9649 (66.4) 9539 (65.6) .17
Prophylactic vitamin A, n (%) 2501 (8.1) 1462 (6.1) .03 1038 (7.1) 774 (5.3) <.001
Prophylactic indomethacin, n (%){ 4103 (13.3) 4752 (20.0) <.001 2115 (14.6) 2744 (18.9) <.001
Pressor therapy, n (%)k 5671 (18.4) 9030 (37.9) <.001 3136 (21.6) 4599 (31.6) <.001
*Early-onset sepsis defined as a positive blood culture before DOL 3. A total of 4755 (8.7%) unmatched patients and 2843 (9.8%) PS-matched patients had missing data.
†IVH grade III or IV.
zMedical or surgical NEC.
xStatistical comparison not performed as groups separated by age at caffeine initiation.
{Prophylactic indomethacin defined as initiation of indomethacin before DOL 3.
kIncludes the use of any of the following cardiac agents: dobutamine, dopamine, epinephrine, norepinephrine, or milrinone.
Table IV. Clinical outcomes
Outcomes
All patients PS-matched patients*
Early caffeine
(n = 30 891)
Late caffeine
(n = 23 816) P value
Early caffeine
(n = 14 535)
Late caffeine
(n = 14 535) OR (99% CI) P value
Primary outcomes, n (%)
BPD or death 6898 (24.3) 8855 (40.2) <.001 3681 (27.6) 4591 (34.0) 0.74 (0.69-0.80) <.001
BPD in survivors† 5823 (20.6) 8068 (36.7) <.001 3070 (23.1) 4154 (30.7) 0.68 (0.63-0.73) <.001
Death 1172 (3.8) 998 (4.2) .08 659 (4.5) 542 (3.7) 1.23 (1.05-1.43) <.001
Secondary outcomes, n (%)
Treatment of PDA 2753 (8.9) 4655 (19.6) <.001 1794 (12.3) 2765 (19.0) 0.60 (0.55-0.65) <.001
Late-onset sepsisz 6021 (21.1) 6361 (29.8) <.001 3083 (21.2) 3559 (24.5) 0.81 (0.76-0.88) <.001
Duration of MV, d
Mean (5th-95th percentile) 10 (0, 46) 21 (0, 73) <.001 11 (0, 48) 17 (0, 64) <.001
Median (IQR) 2 (0-9) 9 (1-34) 3 (1-12) 6 (0-25)
Weight gain, g/d, mean (5th,95th percentile)x
DOL 7 6.3 (24.4, 12.7) 3.3 (23.4, 17.1) <.001 6.3 (25.1, 12.9) 3.5 (23.6, 17.0) <.001
DOL 14 5.8 (5.0, 17.5) 6.1 (5.4, 18.6) .011 5.6 (5.1, 17.1) 6.5 (5.0, 18.9) <.001
DOL 28 13.9 (5.0, 24.1) 13.0 (3.6, 23.9) <.001 13.6 (4.8, 23.6) 13.7 (4.3, 24.4) .40
*Early and late caffeine groups were PS matched on the following baseline variables: GA, birth weight, sex, race, multiple gestation, small for GA, Apgar score at 5 min, any antenatal steroids,
outborn, center, and birth year. In addition, the following early clinical variables on DOL 1 were used: apnea, type of respiratory support, maximal FiO2, and need for HFOV.
†A total of 2195 (4.0%) unmatched infants and 1031 (3.5%) PS-matched infants (early, 558; late, 473) had missing data for BPD.
zA total of 4755 (8.7%) unmatched infants and 2843 (9.8%) PS-matched infants (early, 1379; late, 1464) had missing data for late-onset sepsis.
xMean daily weight gain (or loss) from birth to DOL listed.
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loss was greater during the first week of life (DOL7) in the early
caffeine group (early, 6.3 g/day; late, 3.5 g/day; P < .001);
however, the difference in mean weight gain between the
groups was no longer present by DOL 28 (early, 13.6 g/day;
late, 13.7 g/day; P = .40). Infants in the early caffeine group
experienced fewer days on MV (mean difference, 6 days; P <
.001). The odds of late-onset sepsis were also lower in the
early caffeine group (OR, 0.81; 95% CI, 0.76-0.88).
Trends in Caffeine Use
The use of caffeine demonstrated a shift toward earlier initi-
ation over time (Figure 3; available at www.jpeds.com). The
age at caffeine initiation decreased from a mean of DOL 10
(5th, 95th percentile, 0, 46) and a median of DOL 4 (IQR
2-10) in 1997 to a mean of DOL 4 (5th, 95th percentile, 0,
18) and median of DOL 1 (IQR, 0-3) in 2010. In addition,
caffeine progressively replaced aminophylline and
theophylline as the methylxanthine of choice, accounting
for >90% of methylxanthine use since 2007 and 96% of
methylxanthine use in 2010 (Figure 4; available at www.
jpeds.com). The use of multiple methylxanthines was
common before 2001 and decreased substantially to <5%
of all methylxanthine use after 2007. The percentage of
VLBW infants exposed to caffeine therapy also increased
over time, from 43% in 1999 to 73% in 2010 (Figure 5;
available at www.jpeds.com). Similar trends were seen for
extremely low birth weight (<1000 g) infants.
Discussion
In VLBW infants, early caffeine initiation was associated with
reduced neonatal morbidity, including a decreased incidence
of BPD and of PDA requiring treatment. In addition, the cen-
ters in this study have shifted toward earlier initiation of
caffeine therapy over time, with a majority of VLBW infants
receiving early caffeine therapy in 2010. Although the obser-
vational study design limits our ability to draw inferences
regarding causality, the effect of early caffeine therapy on
improving pulmonary outcomes in VLBW infants is biolog-
ically plausible. Caffeine rapidly improves several functions
involved in effective respiration, including pulmonary
compliance and airway resistance,6,8 minute ventilation,5
and respiratorymuscle contractility.7 Together, these benefits
of caffeine therapy can facilitate earlier weaning from MV or
increase the success of initial CPAP therapy and reduce
ventilator-associated lung injury. This is particularly relevant
in the early neonatal period, when the rate of failure of initial
CPAP therapy is high and when apnea of prematurity–related
symptoms may be prevalent.20 The potential benefits of
caffeine therapy in reducing ventilator-associated lung injury
are supported by our finding of a 6-day reduction in the
mean days on MV in the early caffeine group.
The association of caffeine therapy with a decreased
incidence of PDA requiring treatment is also supported by a
number of candidate biological mechanisms, including
improvements in cardiac function,21 altered fluid balance,22
and effects on signaling pathways involved in ductal constric-
tion.23,24 Caffeine has been associated with increases in
cardiac output and blood pressure in preterm infants21 and
adults.25 In the present study, infants receiving early caffeine
therapy received less pharmacologic treatment of hypoten-
sion. The decreased need for respiratory or cardiac support
may reduce the likelihood of a clinician choosing to treat a
PDA. In addition, excessive fluid intake in the first week of
life is a risk factor for PDA,26 and caffeine, through its diuretic
properties,22 may help optimize early fluid balance in VLBW
infants. The increased weight loss observed in the first week of
life in infants receiving early caffeine therapy may be a result
of caffeine’s diuretic effects or may be secondary to caffeine’s
effects on metabolic demands.27 Regardless, the indications
for treatment of PDA cannot be ascertained from this data-
base and remain controversial in current neonatal practice.28
Interestingly, infants in the early caffeine group had a lower
incidence of PDA despite receiving less frequent treatment
with prophylactic indomethacin, which is known to decrease
the incidence of PDA.29 This finding may suggest that centers
(or clinicians) that used indomethacin prophylaxis were less
likely to initiate early caffeine therapy.
Although not selected as prespecified outcome measures,
decreased incidence of IVH and of ROP were seen in the early
caffeine group. We speculate that the decreased incidence of
ROP in the early caffeine group is a consequence of improved
pulmonary morbidity and a decreased need for ventilation
and exposure to supplemental oxygen. Severe ROP is also
associated with intermittent hypoxia, which may be reduced
by caffeine treatment.30 In the CAP trial, infants allocated to
receive caffeine had a lower incidence of severe ROP.
The association between early caffeine therapy and
decreased IVH, including severe IVH, requires additional
study. A potential mechanism behind this finding is
caffeine’s effect on decreasing cerebral blood flow,31,32 which
may better protect the germinal matrix from hemorrhage.
In our multicenter cohort, the indications for early caffeine
therapy likely varied among the centers. Interestingly, although
apnea symptoms are often reported and documented inconsis-
tently, the incidence of early apnea was low in our cohort,
implying that perhaps apnea was not a common indication
for early initiation of caffeine treatment. In addition, more
than 60% of infants in the early caffeine group received MV
on DOL 1. Thus, we speculate that the infants receiving early
caffeine therapy were treated prophylactically to prevent apnea
or were treated to facilitate weaning from ventilation.
Although BPD prevention is not an accepted indication for
caffeine use, we cannot exclude the possibility that some
centers in this study might have used early caffeine therapy
for this purpose.33 We attempted to account for confounding
variables related to the indication for early initiation of
caffeine therapy by robustly controlling for factors that
potentially could influence early therapy, including baseline
and early respiratory support characteristics, through the
use of PS matching. The association of early caffeine therapy
and decreased BPD remained significant in PS-matched
infants who had a similar GA, birth weight, sex, race, respira-
tory support, and maximal FiO2 on DOL 1. Importantly,
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these 6 variables are the primary predictors of the risk of
BPD.34 The similarity in each of these variables between the
groups reassured us that PS-matched infants in the late
caffeine group did not represent a population with a mark-
edly increased or decreased baseline risk of BPD. In addition,
several of these variables are primary determinants of
neonatal mortality and long-term neurologic outcome.35
Infants receiving early caffeine, particularly those at <24
weeks GA, had a higher incidence of death. Although this
finding is of potential concern, the lower mortality observed
in the late caffeine groupmay be related to a survival bias.Mor-
tality at this GA is high, andmost deaths occur early after birth;
for instance, an infant who received early caffeine (DOL 0-2)
was at risk of dying on DOL 4. In contrast, an infant included
in the late caffeine cohortwho received caffeineonDOL5obvi-
ously could not have died onDOL4. Further study is needed to
confirm this finding in infants born at the earliest GAs.
This study has several limitations. Changes in clinical prac-
tice over the study period might have influenced the clinical
outcomes. Recent data suggest a small decrease in the inci-
dence of BPD over the last decade with no apparent decreases
in mortality.36,37 To account for these potential temporal
changes in outcomes, we included birth year in our
PS-matching model. Another limitation was our inability to
use a physiological definition of BPD, which may be a more
reliable measure of BPD in VLBW infants.38 Owing to limita-
tions in the data available to us, we were unable to capture all
variables that might have influenced the indication for
caffeine initiation or clinical outcomes. These include
maternal variables, such as chorioamnionitis, and therapies,
such as postnatal steroid use for the treatment of severe
lung disease. In addition, the differences in hypotension
requiring treatment, while possibly influenced by caffeine’s
effects on cardiac function,21 might have been equally reflec-
tive of an increased severity of illness in infants receiving late
caffeine therapy. The association between early caffeine initi-
ation and reductions in various neonatal morbidities may
have been affected by treatment and selection bias. Despite
our attempts to address confounding factors, we were unable
to account for all factors that might have influenced early
caffeine therapy or were reflective of early severity of illness.
In addition, it is important to note that the small sample sizes
in the subgroup analyses might have limited our ability to
detect clinically significant differences.
Our findings have important clinical and research impli-
cations for VLBW infants. This study demonstrates that
caffeine is now widely used in preterm infants, with
approximately 70% of all VLBW infants receiving therapy
in 2008-2010. In addition, currently available therapies to
decrease the burden of BPD and PDA are limited. Our
findings are in line with observations from our previous
single-center, retrospective study in which early caffeine
therapy was also associated with a decreased incidence of
BPD or death.13 To our knowledge, these are the only
studies to date to report an association between early
caffeine therapy and reductions in BPD and in PDA
requiring treatment.
Caffeine is already a widely used medication in VLBW in-
fants, but optimizing caffeine therapy to maximize treatment
effects may yield substantial benefits for VLBW infants at risk
for BPD and PDA. Other potential benefits of early caffeine
prophylaxis may include reduced risks of ROP and IVH. A
change in practice toward earlier initiation of caffeine ther-
apy is already occurring, but randomized controlled trials
are needed to investigate the benefits and safety of early
caffeine prophylaxis and its effect on short- and long-term
outcomes. n
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Figure 2. Distribution of infants receiving caffeine therapy by
postnatal age at initiation. Data are presented for a total of
51 623 unmatched infants with birth weight <1500 g who
received caffeine therapy. Infants with caffeine initiation
beyond 28 DOL, representing 5.6% of all patients (n = 3084),
are not depicted.
Figure 3. Mean and median postnatal age at caffeine initia-
tion in VLBW infants, demonstrating a trend toward early
initiation of caffeine therapy over time. R2 = 0.89 for negative
correlation between birth year and mean age at caffeine
initiation. Whisker bars indicate 95% CI for mean values and
IQR for median values.
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Figure 5. Percentages of VLBW and extremely low birth
weight infants exposed to caffeine during hospitalization.
Whisker bars indicate 95% CIs. ELBW, extremely low birth
weight.
Figure 4. Percentage of VLBW infants receiving methylxan-
thine therapy as a fraction of overall methylxanthine use (top)
and number of VLBW infants receiving methylxanthines
(bottom). Exclusive use of caffeine increased from 26% in
1997 to 96% in 2010. Treatment with methylxanthines other
than caffeine, including multiple methylxanthines, predomi-
nated before 2001 and was infrequent after 2007 (<5%).
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Table II. Respiratory support characteristics
Respiratory characteristics
PS-matched patients
Early caffeine (n = 14 523) Late caffeine(n = 14 498) P value
Characteristics at caffeine initiation
Respiratory support at caffeine initiation, n (%)*
Room air 1116 (7.7) 2624 (18.1) <.0001
Hood oxygen 86 (0.6) 51 (0.4)
Nasal cannula 509 (3.5) 1635 (11.3)
High-frequency nasal cannula 609 (4.2) 1118 (7.7)
CPAP 3131 (21.6) 2545 (17.6)
MV 7562 (52.1) 5678 (39.2)
HFOV 1510 (10.4) 847 (5.8)
Maximal FiO2 at caffeine initiation
Mean (5th-95th percentile) 0.28 (0.21-0.50) 0.28 (0.21-0.50) .97
Median (IQR) 0.21 (0.21-0.30) 0.22 (0.21-0.30)
Characteristics at 36 0/7 weeks PMA†
Infants evaluated at 36 0/7 weeks PMA, n 8879 9813
Respiratory support at 36 0/7 weeks PMA, n (%)
Room air 4949 (55.7) 4713 (48.0) <.0001
Hood oxygen 68 (0.8) 163 (1.0)
Nasal cannula 2439 (27.5) 3081 (31.4)
High-frequency nasal cannula 482 (5.4) 656 (6.7)
CPAP 522 (5.9) 639 (6.5)
MV 375 (4.2) 565 (5.8)
HFOV 44 (0.5) 64 (0.7)
Receipt of FiO2 >0.21, n (%) 3064 (34.8) 4150 (42.7) <.0001
Receipt of FiO2 >0.30, n (%) 1972 (22.4) 2653 (27.3) <.0001
PMA, postmenstrual age.
*A total of 49 (0.2%) PS-matched patients with missing data.
†For the early caffeine group, 659 (4.5%) infants died before discharge, 4439 (30.5%) were evaluated before 36 weeks PMA, and 558 (3.8%) had missing data. For the late caffeine group, 542 (3.7%)
infants died before discharge, 3707 (25.5%) were evaluated before 36 weeks PMA, and 473 (3.3%) had missing data.
Table V. Primary outcome by GA subgroup
GA
BPD in survivors Death BPD or death
Early
caffeine, n (%)
Late
caffeine, n (%)
OR
(99% CI)
Early
caffiene, n (%)
Late
caffiene, n (%)
OR
(99% CI)
Early
caffiene, n (%)
Late
caffiene, n (%)
OR
(99% CI)
<24 wk 86 (43.7) 538 (67.1) 0.38 (0.25-0.58) 80 (33.2) 132 (15.3) 2.76 (1.77-4.28) 163 (82.7) 645 (80.4) 1.17 (0.68-2.08)
24-28 wk 4346 (29.0) 5996 (49.7) 0.41 (0.39-0.44) 927 (5.5) 745 (5.6) 0.99 (0.87-1.13) 5205 (34.8) 6592 (54.7) 0.44 (0.41-0.47)
29-32 wk 1274 (10.9) 1340 (17.2) 0.59 (0.53-0.66) 140 (1.1) 97 (1.2) 0.97 (0.69-1.36) 1395 (12) 1412 (18.1) 0.62 (0.55-0.68)
>32 wk 109 (7.3) 177 (13.4) 0.51 (0.36-0.71) 21 (1.4) 22 (1.6) 0.83 (0.38-1.84) 123 (8.2) 188 (14.2) 0.54 (0.39-0.74)
Data are from all patients (matched and unmatched).
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